Research and Development Agreement (CRADA) with the US National Institute of Health (NIH)Cooperative Research and Development Agreement (Crada) • July 18th, 2011
Contract Type FiledJuly 18th, 2011Can-Fite BioPharma announced today on the signing of a Cooperative Research and Development Agreement (CRADA) with the National Institute of Health in the US. The CRADA relates to new small molecules that are agonists of the A3 adenosine receptor (A3AR), invented in the laboratory of Prof. Kenneth A. Jacobson from the NIH. The A3AR is the prime target of Can- Fite’s drug development efforts. The focus of the CRADA will be to identify such agonists with potential therapeutic use in the treatment of autoimmune inflammatory diseases and cancer.